

姓名	孔德新	职称	教授	所在部门	临床药系	研究方向	分子靶向药物	
办公室	B304	办公电话	83336673	电子邮箱	kongdexin@tmu.edu.cn			

教育背景

2002/04—2005/03, 大阪大学药学部, 博士
 1991/09—1994/07, 山东大学药学院, 硕士
 1987/09—1991/07, 山东大学药学院, 学士

工作经历

2010/10-至今, 天津医科大学药学院教授, 天津市基础医学研究中心 PI
 2010/04—2010/10, 日本癌症研究所分子药理部, 资深研究员 (永久职位)
 2006/08—2010/03, 日本癌症研究所分子药理部, 研究员
 2005/04—2006/07, 香港中文大学药学院, 副研究员
 2000/10—2002/03, 大阪大学药学部, 访问学者
 1996/12—2000/09, 山东大学生命科学学院, 讲师
 1994/08—1996/11, 山东大学生命科学学院, 助教

研究成果 (本人第一或通讯作者论文, 及主持的科研项目)

论文	<h4>近年来发表主要期刊论文</h4> <ol style="list-style-type: none"> 1. Peng X, Zhang S, Jiao W, Zhong Z, Yang Y, Claret FX, Elkabets M, Wang F, Wang R, Zhong Y, Chen ZS, Kong D. Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway. <i>J Exp Clin Cancer Res.</i> 2021; 40(1): 374. 2. Zhang Z, Hou L, Yu Z, Xu Z, Li S, Wang Y, Liu H, Zhao B, Liu R, Wang W, Du B, Zhong Y, Kong D. Biomimetic Small-Molecule Self-Assembly of PI3K inhibitor integrated with immunomodulator to amplify anticancer efficacy <i>Chem Eng J.</i> 2021;407:133747. 3. Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R, Zhong Y, Kong D. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. <i>Cell Death Dis.</i> 2021;12(6):546. 4. Zhao X, Zhang N, Huang Y, Dou X, Peng X, Wang W, Zhang Z, Wang R, Qiu Y, Jin M, Kong D. Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo. <i>Front Cell Dev Biol.</i> 2021;9:655559. 5. Shao C, Huang Y, Fu B, Pan S, Zhao X, Zhang N, Wang W, Zhang Z, Qiu Y, Wang R, Jin M, Kong D. Targeting c-Jun in A549 Cancer Cells Exhibits Antiangiogenic Activity In Vitro and In Vivo Through Exosome/miRNA-494-3p/PTEN Signal Pathway. <i>Front Oncol.</i> 2021;11:663183. 6. Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, Xu Y, Wang R, Wang W, Kong D. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome
----	---

	<p>Inhibition in Human Ovarian Cancer Cells. <i>Recent Pat Anticancer Drug Discov.</i> 2021;16(3):350-362.</p> <ol style="list-style-type: none"> 7. Zhu S, Jiao W, Xu Y, Hou L, Li H, Shao J, Zhang X, Wang R, Kong D. Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway. <i>Life Sci.</i> 2021 Dec 1;286:120046. 8. Wang Y, Hou Y, Hou L, Wang W, Li K, Zhang Z, Du B, Kong D. Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway. <i>Biosci Rep.</i> 2021 Oct 29;41(10):BSR20211056. 9. Zhang Z, Hou L, Yu Z, Xu Z, Li S, Wang Y, Liu H, Zhao B, Liu R, Wang W, Du B*, Zhong Y*, Kong D*. Biomimetic Small-Molecule Self-Assembly of PI3K inhibitor integrated with immunomodulator to amplify anticancer efficacy <i>Chem Eng J.</i> 2021;407:133747. 10. Zhang Z, Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Liu R, Wang W, Du B, Zhong Y, Kong D*. Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo. <i>Chem Eng J.</i> 2020; 406:126801 11. Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, Wang W, Lin P, Zhang Z, Zhong Y, Kong D*. Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. <i>Front Pharmacol.</i> 2020, 11:186. 12. Shunli Pan, Xiaoxia Zhao, Chen Shao, Bingjie Fu, Yingying Huang, Ning Zhang, Xiaojing Dou, Zhe Zhang, Yuling Qiu, Ran Wang, Meihua Jin, Kong D*. STIM1 promotes angiogenesis by reducing exosomal miR-145 in breast cancer MDA-MB-231 cells. <i>Cell Death Dis.</i> 2021, 12: 38. 13. Yong-Qiang Hou, Ying-Ying Wang, Xing-Can Wang, Yao Liu, Chun-Ze Zhang, Zhe-Sheng Chen, Zhe Zhang, Wei Wang, De-Xin Kong. Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro. <i>Gastroenterol Rep.</i> 2020, 8: 465-475. 14. Zhang L, Chen T, Dou Y, Zhang S, Liu H, Khishignyam T, Li X, Zuo D, Zhang Z, Jin M, Wang R, Qiu Y, Zhong Y, Kong D*. Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells. <i>Front. Oncol.</i> 2019;9:1032. 15. Peng X, Liu Y, Zhu S, Peng X, Li H, Jiao W, Lin P, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma. <i>J Cancer Res Clin Oncol.</i> 2019;145: 2921-2936. 16. Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D*. Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. <i>Front Oncol.</i> 2019, 9:514. 17. Pan S, Zhao X, Ji N, Shao C, Fu B, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Inhibitory effect of taxifolin on mast cell activation and mast cell-mediated allergic inflammatory response. <i>Int Immunopharmacol.</i> 2019, 71:205-214. 18. Zhang Z, Liu J, Wang Y, Tan X, Zhao W, Xing X, Qiu Y, Wang R, Jin M, Fan G, Zhang P, Zhong Y, Kong D*. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells. <i>FASEB J.</i> 2018, 32: 5967-5975. 19. Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D*,
--	---

- Chen ZS. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. *Cancer Lett.* 2019, 440-441:82-93.
20. Zhao W, Qiu Y, Kong D*. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. *Acta Pharmaceutica Sinica B*, 2017, 7:27-37.
 21. Wang Z, Wang Y, Zhu S, Liu Y, Peng X, Zhang S, Zhang Z, Qiu Y, Jin M, Wang R, Zhong Y, Kong D*. DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway. *Front Pharmacol.* 2018, 9:1450.
 22. Liu J, Tan X, Zhao W, Liu J, Xing X, Fan G, Zhang P, Zhang Z, Zhong Y, Kong D*. In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells. *Curr Cancer Drug Targets.* 2018, 18:1-9.
 23. Ji N, Yang Y, Lei ZN, Cai CY, Wang JQ, Gupta P, Xian X, Yang DH, Kong D*, Chen ZS*. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. *Biochem Pharmacol.* 2018, 158:274-285.
 24. Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Teng QX, Chen ZS, Kong D*, Yang DH*. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. *Front Pharmacol.* 2018, 30,9:1236.
 25. Ji N, Pan S, Shao C, Chen Y, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Spinacetin Suppresses the Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mouse Model. *Front Pharmacol.* 2018, 9:824.
 26. Peng X, Liu Y, Peng X, Wang Z, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Clinical features and the molecular biomarkers of olfactory neuroblastoma. *Pathol Res Pract.* 2018, 214:1123-1129.
 27. Peng X, Wang Z, Liu Y, Peng X, Liu Y, Zhu S, Zhang Z, Qiu Y, Jin M, Wang R, Zhang Q, Kong D*. Oxyfadichalcone C inhibits melanoma A375 cell proliferation and metastasis via suppressing PI3K/Akt and MAPK/ERK pathways. *Life Sci.* 2018, 206:35-44.
 28. Zhang L, Wang Z, Khishignyam T, Chen T, Zhou C, Zhang Z, Jin M, Wang R, Qiu Y, Kong D*. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells. *Biomed Pharmacother.* 2018, 103:1069-1078.
 29. Peng X, Zhou C, Hou X, Liu Y, Wang Z, Peng X, Zhang, Wang R, Kong D*. Molecular characterization and bioactivity evaluation of two novel bombinin peptides from the skin secretion of Oriental fire-bellied toad, *Bombina orientalis*. *Amino Acids.* 2018, 50:241-253.
 30. Zhou C, Wang Z, Peng X, Liu Y, Lin Y, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Discovery of two Bombinin peptides with antimicrobial and anticancer activities from the skin secretion of Oriental Fire-bellied toad, *Bombina orientalis*. *Chem Biol Drug Des.* 2018, 91:50-61.
 31. Zhou Q, Chen Y, Zhang L, Zhong Y, Zhang Z, Wang R, Jin M, Gong M, Qiu Y, Kong D*. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells. *Oncotarget*, 2017, 8:39064-39076.
 32. Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, Wang R, Jin M, Qiu Y, Kong D*. Stelletin B induces apoptosis in human chronic myeloid leukemia cells via

	<p>targeting PI3K and Stat5. <i>Oncotarget</i>, 2017, 8: 28906-28921.</p> <p>33. Chen Y, Ji N, Pan S, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-κB and MAPK Pathway in RAW264.7 Cells. <i>Inflammation</i>, 2017, 40:1959-1966.</p>
科研项目	<ol style="list-style-type: none"> 1. 国家自然科学基金国际合作研究项目, 新型 PI3K 抑制剂的纳米递送增强免疫治疗对 PIK3CA 突变头颈癌疗效的研究, 200 万元, 2020.10-2023.09。 2. 国家自然科学基金面上项目, 基于 STELB 抑制同源重组修复的联合用药抗胶质母细胞瘤研究, 55 万元, 2021.01-2024.12。 3. 国家自然科学基金面上项目 (81673464), STELB 抑制胶质母细胞瘤的作用、分子机制及靶点研究, 54 万元, 2017.01-2020.12。 4. 国家自然科学基金国际合作项目 (81881340655), 精准医疗背景下创新药物的发现与研发, 6 万元, 2018.09-2018.12。 5. 国家自然科学基金面上项目 (81373441), 以小分子探针研究靶向 PI3K 亚型抑制前列腺癌转移的作用及多重分子机理, 60 万元, 2013.01-2017.12。 6. 日本学术振兴会“桥”项目国际交流基金(编号 BR13102),从天然资源(包括海洋生物)中发现分子靶向药物的方法学研究, 10 万元, 2013 年 7 月至 2014 年 3 月。 7. 日本学术振兴会外国资深研究者访问交流基金(编号 S-12105), 新型分子靶向药物的发现, 15 万元, 2012 年 4 月至 2013 年 3 月。 8. 天津市新药创制重大科技专项 (17XXYSY00050), 抗肿瘤药物靶点发现平台 KTC21 的建设, 100 万元, 2017.10-2020.09. 9. 天津市自然科学基金重点项目 (12JCZDJC25800), 靶向抑制 PI3K 对前列腺癌转移的影响及机理研究, 20 万元, 2012.04-2015.03. 10. 天津市教委创新团队项目, 天津市高等学校临床药学创新团队培养计划, 180 万元, 2013.12-2015.11.
荣誉奖励	
<p>天津市特聘教授, 天津市重点领域创新团队“分子靶向药物研究创新团队”负责人, 天津市高校药理学学科领军人才, 山西省百人计划。日本学术振兴会中国同学会第 3 任会长、中国抗癌协会抗癌药物专委会常委、中国药理学会肿瘤药理专委会常委、中国生化与分子生物学会工业生化与分子生物学会常务理事、中国老年学和老年医学学会肿瘤基础及转化研究专家委员会常委等。</p>	
其他事项	
<p>Frontiers in Pharmacology 等期刊 Guest editor, British Journal of Pharmacology、Cancer Letters、APSB 等 20 余种期刊审稿人。国家自然科学基金、科技部重大研发计划会审和函审专家。</p>	